When Pandemic Ends, EUA Recipients May Face Litigation And Enforcement Actions
Manufacturers face risk of whistle-blower suits and government enforcement actions when emergency use authorizations expire and pandemic recedes, attorneys say, but interaction with FDA and documentation may mitigate risk.
You may also be interested in...
Scrip discusses with a cross-section of experts the complexities around pursuing compensation for COVID-19 vaccine-related injuries in India. Is there a case for ‘absolute liability’ for all injuries related to the two fast-tracked vaccines currently available, or alternatively a no-fault compensation program?
The US Department of Health and Human Services is offering some legal protection to developers of devices and diagnostics for use in the fight against the novel coronavirus.
System needs to be changed to enable US FDA to share COVID-19 application data and inspection reports with other regulatory authorities, stakeholders urge. Merck’s Julie Gerberding and former FDA Commissioner Hamburg criticize company announcement of data via press release prior to submission.